The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.

ABSTRACT:

Background

High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need to develop tools to improve patient outcomes. Patient-derived xenograft (PDX) models, such as mouse PDX, have emerged as potential Avatar platforms for personalized oncology approaches, but the difficulty for some human grafts to grow successfully and the long time required for mice to develop tumors preclude their use for HGG.

Methods

We used a rapid and efficient ex-ovo chicken embryo chorioallantoic membrane (CAM) culture system to evaluate the efficacy of oncologic drug options for HGG patients.

Results

Implantation of fresh glioma tissue fragments from 59 of 60 patients, that include difficult-to-grow ID

SUBMITTER: Charbonneau M 

PROVIDER: S-EPMC10479744 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature